Haines, David E. http://orcid.org/0000-0002-5592-8338
Kong, Melissa H.
Ruppersberg, Peter
Haeusser, Philip
Avitall, Boaz
Szili-Torok, Tamas
Verma, Atul
Article History
Received: 15 June 2022
Accepted: 15 July 2022
First Online: 15 August 2022
Change Date: 15 October 2023
Change Type: Update
Change Details: Springer Nature’s version of this paper was updated: In this article the author name "Tamas Szili-Torok" was incorrectly written as "Tamas Szili Torok".
Declarations
:
: Preclinical experiments referenced in the manuscript were performed in AAALAC-accredited institutions. The Ablacon Ablamap technology has received CE Mark and FDA 510(k) approval. All patient observations presented were derived from published human studies or from the randomized, controlled FLOW-AF study (NCT 04473963) approved by local investigational review boards, and after patient informed consent.
: Authors’ potential conflicts of interest are as follow: DH: Ablacon Scientific Advisor, Equity; MK: employee of Ablacon; PR: employee of Ablacon; PH: employee of Ablacon; BA: Ablacon paid consultant; TS: Ablacon paid consultant and investigator in FLOW-AF trial; AV: Ablacon Scientific Advisor, Equity.